NCT01922336已完成1 期
A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Infliximab (SB2, EU Sourced Remicade® and US Sourced Remicade®) in Healthy Subjects
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 159
- 试验地点
- 1
- 主要终点
- Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
研究概览
简要总结
The purpose of this study is to compare the pharmacokinetics, safety, tolerability and immunogenicity of SB2 and Remicade (EU sourced Remicade and US sourced Remicade) in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy female subjects of non-childbearing potential and healthy male subjects
- •Have a body weight between 60.0 and 94.9 kg and a body mass index between 20.0 and 29.9 kg/m², inclusive.
排除标准
- •history and/or current presence of clinical significant atopic allergy, hypersensitivity or allergic reactions, also including known or suspected clinically relevant drug hypersensitivity to any components of the test and reference IP formulation or comparable drugs.
- •active or latent Tuberculosis or who have a history of Tuberculosis.
- •history of invasive systemic fungal infections or other opportunistic infections
- •systemic or local infection, a known risk for developing sepsis and/or known active inflammatory process
- •serious infection associated with hospitalisation and/or which required intravenous antibiotics
- •history of and/or current cardiac disease
- •have received live vaccine(s) within 30 days prior to Screening or who will require live vaccine(s) between Screening and the final study visit.
- •Intake medication with a half-life > 24 h within 1 month or 10 half-lives of the medication prior to the administration of investigational product.
研究组 & 干预措施
EU Remicade
Active Comparator
EU sourced Remicade (Reference drug)
干预措施: EU Remicade (Biological)
US Remicade
Active Comparator
US sourced Remicade (Reference drug)
干预措施: US Remicade (Biological)
SB2
Experimental
SB2 (Study drug)
干预措施: SB2 (Biological)
结局指标
主要结局
Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
时间窗: 71 days
Maximum Serum Concentration (Cmax)
时间窗: 71 days
Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)
时间窗: 71 days
次要结局
- Time to Cmax (Tmax)(71 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male SubjectsHealthyNCT02075073Samsung Bioepis Co., Ltd.109
已完成
1 期
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy SubjectsHealthyNCT02144714Samsung Bioepis Co., Ltd.189
已完成
1 期
Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Two Formulations of SB5 in Healthy Male SubjectsHealthyNCT04514796Samsung Bioepis Co., Ltd.188
Unknown
3 期
Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B-cell LymphomaNCT03777085Chia Tai Tianqing Pharmaceutical Group Co., Ltd.230
已完成
1 期
First Time in Human Study of ProtexiaIntervention for Nerve Agent ExposureNCT00744146PharmAthene, Inc.33